Education
About Us
Working with TipRanks
Follow Us
Merck KGaA (DE:MRK)
XETRA:MRK
MRK Stock Chart & Stats
Day’s Range― - ―
52-Week Range€110.45 - €177.00
Previous CloseN/A
Volume8.13K
Average Volume (3M)388.44K
Market Cap
€49.80B
Enterprise Value€60.48B
Total Cash (Recent Filing)€2.71B
Total Debt (Recent Filing)€10.27B
Price to Earnings (P/E)17.9
Beta0.70
Next Earnings
Aug 07, 2025EPS Estimate
2.17Last Dividend Ex-Date
Apr 28, 2025Dividend Yield1.92%
Share Statistics
EPS (TTM)2.12
Shares Outstanding129,242,250
10 Day Avg. Volume421,524
30 Day Avg. Volume388,438
Financial Highlights & Ratios
PEG Ratio6.66
Price to Book (P/B)1.79
Price to Sales (P/S)0.00
P/FCF Ratio25.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€164.33Price Target Upside43.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
---
Merck KGaA News
---
Bulls Say, Bears Say
Bulls Say
Electronics DivisionElectronics recovery is playing out due to AI, improving the profile of the division.
Growth ExpectationsA return to growth in Life Sciences and Process Solutions for the first time in five quarters is expected to give additional confidence to investors on future growth expectations.
ValuationAnalyst re-iterates BUY as MRK is attractively valued compared to its end markets and peers.
Bears Say
EBITDA QualityThere is a negative perception surrounding Healthcare-driven EBITDA beats due to cost releases, which investors might see as lower quality compared to topline-driven growth.
Life Sciences ChallengesThere is a clear lack of visibility on FY25 Life Sciences trends, with Bioprocessing numbers below mid-term expectations.
Sales ExpectationsThe guidance indicates that the upper end of the sales range is out of reach, aligning with previous messaging but possibly disappointing investors hoping for higher sales figures.
---
Options Prices
Currently, No data available
---
Ownership Overview
― Insiders
13.38%
Mutual Funds
<0.01% Other Institutional Investors
71.98% Public Companies and
Individual Investors
MRK FAQ
What was Merck KGaA’s price range in the past 12 months?
Merck KGaA lowest stock price was €110.45 and its highest was €177.00 in the past 12 months.
What is Merck KGaA’s market cap?
Merck KGaA’s market cap is €49.80B.
When is Merck KGaA’s upcoming earnings report date?
Merck KGaA’s upcoming earnings report date is Aug 07, 2025 which is in 80 days.
How were Merck KGaA’s earnings last quarter?
Merck KGaA released its earnings results on May 15, 2025. The company reported €2.12 earnings per share for the quarter, missing the consensus estimate of €2.159 by -€0.039.
Is Merck KGaA overvalued?
According to Wall Street analysts Merck KGaA’s price is currently Undervalued.
Does Merck KGaA pay dividends?
Merck KGaA pays a Annually dividend of €2.2 which represents an annual dividend yield of 1.92%. See more information on Merck KGaA dividends here
What is Merck KGaA’s EPS estimate?
Merck KGaA’s EPS estimate is 2.17.
How many shares outstanding does Merck KGaA have?
Merck KGaA has 129,242,250 shares outstanding.
What happened to Merck KGaA’s price movement after its last earnings report?
Merck KGaA reported an EPS of €2.12 in its last earnings report, missing expectations of €2.159. Following the earnings report the stock price went down -6.823%.
Which hedge fund is a major shareholder of Merck KGaA?
Currently, no hedge funds are holding shares in DE:MRK
---
Merck KGaA Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€164.33 (43.46% Upside)
€164.33 (43.46% Upside)
Insider Transactions
Bought Shares
Worth €1.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.61%
12-Months-Change
Fundamentals
Return on Equity
9.81%
Trailing 12-Months
Asset Growth
6.05%
Trailing 12-Months
Company Description
Merck KGaA
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and electronics sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat neurology and immunology, oncology, fertility, and cardiology metabolism and endocrinology. The company also supplies products, tools, and services for research laboratories, pharma and biotech production, and industrial and testing laboratories. In addition, it offers material for integrated circuits, liquid crystals, organic light-emitting diodes, photoresists, smart antenna, and liquid crystal glazing solutions, as well as effect pigments for use in automotive coatings, cosmetics, industrial, and plastic applications. It has strategic alliances with Pfizer Inc.; agreement with Novartis AG; and license agreements with Debiopharm International SA and MoonLake Immunotherapeutics AG. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.
---
MRK Stock 12 Month Forecast
Average Price Target
€164.33
▲(43.46% Upside)
Technical Analysis
Bayer
―
Fresenius Medical Care AG & Co. KGaA
―
Fresenius SE & Co. KGaA
―
Rheinmetall
―
Sartorius
―
---